Influenza virus vaccine

Details Influenza virus vaccine Influenza virus vaccine

1974-10-04

1976-11-02

Rosen, Sam

Drug, bio-affecting and body treating compositions

Lymphokine

A61K 3918

Patent

active

039898180

ABSTRACT:
Influenza virus is purified, fractionated or concentrated in an aqueous medium, using a linear filamentary non-charged polymer, preferably polyethylene glycol, as an insolubilising agent, at a concentration not exceeding 5% by weight. Impurities and large virus particles can be fractionated off at PEG concentrations of say up to 1%. Phase separation is achieved most readily when assisted by ultra-centrifugation at low temperature between 0.degree. and 6.degree. C. Precipitation of the virus from dispersions of comparatively high concentration (say 600 HA units or more per ml.) results in intimately aggregated virus particles, which are easier to further purify, and which result in an improved vaccine. Novel concenrates of globular influenza virus are also described.

REFERENCES:
patent: 3629470 (1971-12-01), Kanarek et al.
Albrecht ova et al. -- Biologia Plantarum (Praha) vol. 12 No. 1 (1970) pp. 31-40.
Polson -- Hemophilia (International Symposium (1968) pp. 77-82.

Affiliated with

Also associated with

Rating

Influenza virus vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Influenza virus vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Influenza virus vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1160010